Trial Profile
Lp-PLA2, Progenitor Cells and Coronary Atherosclerosis in Humans AIM III
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Oct 2023
Price :
$35
*
At a glance
- Drugs Darapladib (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms AIM-III
- 02 Nov 2017 Results (n=54) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
- 07 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record. (NCT01067339)
- 22 Sep 2015 Planned End Date changed from 1 Apr 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.